Table 3 Characteristics of the 141 patients included in the study
From: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
P53 mutation | MDM2 TT | |||
|---|---|---|---|---|
No | Yes | No | Yes | |
88 (62%) | 53 (38%) | 82 (58%) | 59 (42%) | |
Age (years) | ||||
≤73 | 49 (64%) | 27 (36%) | 44 (58%) | 32 (42%) |
>73 | 39 (60%) | 26 (40%) | 38 (58%) | 27 (42%) |
Gender | ||||
Male | 72 (62%) | 44 (38%) | 66 (57%) | 50 (43%) |
Female | 16 (64%) | 9 (36%) | 16 (64%) | 9 (36%) |
MDM2 | ||||
TT | 38 (64%) | 21 (36%) | - | - |
GG | 11 (61%) | 7 (39%) | - | - |
TG | 39 (61%) | 25 (39%) | - | - |
p53 mutation | ||||
Yes | - | - | 32 (60%) | 21 (40%) |
No | - | - | 50 (57%) | 38 (43%) |
Recurrence | ||||
Yes | 75 (65%) | 40 (35%) | 66 (57%) | 49 (43%) |
No | 13 (50%) | 13 (50%) | 16 (62%) | 10 (38%) |
Progression | ||||
Yes | 30 (57%) | 23 (43%) | 27 (51%) | 26 (49%) |
No | 58 (66%) | 30 (34%) | 55 (62%) | 33 (38%) |